| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMEA/CHMP/537777/2008 (23.10.08) |
| Publication Date | 23/10/2008 |
| Content Type | News |
|
The European Medicines Agency (EMEA), on 23 October 2008, recommended the suspension of the marketing authorisation for Acomplia (rimonobant) from Sanofi-Aventis. The EMEA Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Acomplia no longer outweigh its risks and the marketing authorisation should be supsended across the European Union. |
|
| Source Link | Link to Main Source http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
